Oncology
Analyze adverse events and treatment patterns in Immuno-Oncology through LynxCare's Real-World Datasets
Gain fresh insights into the relationship of specific comorbidities, adverse events and biomarkers with immuno-oncology prognosis through LynxCare's European data asset.
In the realm of immuno-oncology, we recognize the pivotal role that randomized clinical trials play. However, in the majority of RCTs, patients with significant comorbidities are excluded. Yet these patients represent a substantial portion of the immuno-oncology patient population.
Our vast and validated European datasets* address this knowledge gap, offering insights into the relationship of specific comorbidities, adverse events and biomarkers with immuno-oncology prognosis.
Read more on the insights in immuno-oncology we can unlock.
➡ CLICK HERE
* LynxCare datasets concern datasets within the LynxCare hospital network. The hospitals are the data controllers. No commitment before site approval on RWE request.
